Next Generation Precision Radiopharmaceuticals for Patients with Cancer    Watch Video

Ann Marie is the Vice President of Patient Access and Advocacy at Blue Earth Diagnostics. She leads a team focused on educating customers and patients about prostate imaging, developing health policy, working with legislators and government officials, and advocating for change. She also is the Chair of the Medical Imaging & Technology Alliance (MITA) PET Coding, Coverage and Payment Committee.

Understanding Social Determinants of Health and Impact on the Prostate Cancer Racial Disparity    Watch Video

Ms. Contreras joined Dana-Farber in 2007 and currently oversees the Community Health and Community Benefits programs. In this role, she is charged with helping the Institute carry out its Community Benefits mission through the delivery of evidence-based cancer prevention, screening and early detection programs and working across the cancer continuum to help improve cancer care outcomes for medically underserved populations.

Financial Toxicities and How Access to Treatment are Affected     Watch Video

Dr. Hala Borno is faculty at UCSF and an Assistant Professor in the Department of Medicine and Division of Hematology/Oncology and co-Medical Director of the Genitourinary Medical Oncology Clinic at the Helen Diller Family Comprehensive Cancer Center (HDFCCC) at the University of California San Francisco (UCSF). Dr. Borno is a medical oncologist with clinical expertise in the management of advanced urologic malignancies such as prostate, kidney, bladder, and testicular cancers. At HDFCCC, Dr. Borno serves on the executive leadership committee for the Prostate Cancer Program and the Liaison to the Office of Community Engagement. She is also a member of

Considerations for the Management of Advanced Prostate Cancer    Watch Video

Dr. Jacob Berchuck is a Medical Oncologist in the Lank Center for Genitourinary Oncology at Dana-Farber/Brigham and Women’s Cancer Center. Dr. Berchuck received his undergraduate and medical degrees from Duke University. He trained in Internal Medicine at the University of California San Francisco. He then completed a fellowship in Medical Oncology at the Dana-Farber Cancer Institute. In addition to caring for patients, Dr. Berchuck conducts research using cell-free DNA to develop “liquid biopsies” for early and accurate cancer detection.

Dr. Mark Pomerantz is a medical oncologist at the Dana-Farber Cancer Institute. Dr. Pomerantz received his undergraduate degree from Yale University and his medical degree from Stanford University. He trained in Internal Medicine at Brigham and Women’s Hospital in Boston, Massachusetts. He then pursued a fellowship in Medical Oncology at the Dana-Farber Cancer Institute in Boston. Dr. Pomerantz received his post-doctoral training in cancer genetics with Dr. Matthew Freedman at the Dana-Farber Cancer Institute and the Broad Institute of Harvard and MIT. He is on faculty at the Dana-Farber Cancer Institute in the Lank Center for Genitourinary Oncology.

Watch Video – Discusses the Incorporation of the PHEN Early Detection Screening Program in Luminis Healthcare Practice

Dr. Waseem Hussain is Associate Regional Medical Director for Primary Care and a practicing family physician in the Luminis Healthcare System.  He graduated from the University of Maryland School of Medicine, completed his family practice residency in Chicago, and has been a practicing board certified family physician since 1999. He is also  a multiple-time  winner of Washingtonian Magazine’s Top Doctor and Castle Connelly Top Doctor Award, became a Fellow in the American Association of Family Physicians in 2007,  and was recently given the Luminis Health Physician.